Liquid biopsies have been used to test for resistance mutations in some reports [1, 2]; however, it has not been applied currently within routine clinical practice. Liquid biopsy may be particularly useful if biopsies or re-biopsies cannot be performed, if the original biopsy is old, if there are concerns about material degradation, or when RNA testing cannot be done with blood samples. Finally, liquid biopsies can potentially be used to analyse circulating tumour DNA over the course of management of TRK fusion cancers .
- Hofman P. Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology. Cancers (Basel) 2017; 9: pii: E154. doi: 110.3390/cancers9110154.
- Russo M, Misale S, Wei G et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discov 2016; 6: 36-44.
- Wan JCM, Massie C, Garcia-Corbacho J et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017; 17: 223-238.